Elotuzumab, Iberdomide, and Dexamethasone after Ide-cel for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and have tried at least 4 prior treatments, including an immunomodulating drug, a proteasome inhibitor, and a CD38-targeting antibody.
- You have received ide-cel (a CAR T-cell therapy) within the last 90 days and achieved at least a partial response to it.
- You are 18 years old or older and able to care for yourself (ECOG score of 0-2).
- You have adequate blood counts (like neutrophils, platelets, and hemoglobin) and kidney and liver function.
- You have not taken iberdomide before and are not on certain medications that could interfere.
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four cancer-fighting drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) followed by a stem cell transplant for people newly diagnosed with multiple myeloma. The goal is to see if this approach can help patients live longer and control their disease better.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests giving the drug iberdomide before collecting your T cells for CAR-T therapy. The goal is to make the T cells stronger so the CAR-T treatment may work better against your multiple myeloma.
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.